Biotechnology News and Research

RSS

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.

5 Jan 2010

Dow AgroSciences to receive global license to develop and commercialize COT102 transgenic event

Syngenta and Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced today that Syngenta has granted Dow AgroSciences licenses to a number of VipCot(TM) cotton varieties, as well as access to its COT102 cotton transgenic event.

5 Jan 2010

BioPlex 2200 Anti-CCP test for early detection of RA launched

Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research and clinical diagnostics products, and Axis-Shield plc, an international in-vitro diagnostics (IVD) company, today announced the launch of Bio-Rad's BioPlex® 2200 Anti-CCP test for the early detection of rheumatoid arthritis.

5 Jan 2010

Protein interaction linked to AMD

Researchers at University College London say they have gleaned a key insight into the molecular beginnings of age-related macular degeneration, the No. 1 cause of vision loss in the elderly, by determining how two key proteins interact to naturally prevent the onset of the condition.

5 Jan 2010

Vienna scientists develop new technique for producing H1N1 vaccines

Scientists in Vienna have developed a new technique for producing vaccines for H1N1, 'swine flu', based on insect cells. The research, published today in the Biotechnology Journal, reveals how influenza vaccines can be produced faster than through the traditional method of egg-based production, revealing a new strategy for the fight against influenza pandemics.

5 Jan 2010

Biological Industries named exclusive distributor of ATCC products in Israel

ATCC today announced a distribution and development partnership with Biological Industries Ltd. to become the exclusive distributor of ATCC products in Israel. The Israel-based organization is now the newest member of the global network of distributors for ATCC.

5 Jan 2010

CBI signs definitive share purchase agreement to acquire GL Biochem

Commonwealth Biotechnologies, Inc. (“CBI”) is pleased to announced it has entered into a revised and binding definitive share purchase agreement to acquire the parent of Shanghai-based GL

4 Jan 2010

FDA grants Priority Review designation for InterMune's NDA for pirfenidone

InterMune, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review designation for the company's New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

4 Jan 2010

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), one of Japan's leading biopharmaceutical companies, announced today that the two companies have entered into a research collaboration and license agreement for the research, development and commercialization of drug delivery systems and DsiRNA pharmaceuticals for therapeutic targets in oncology.

4 Jan 2010

Revance Therapeutics closes $35 million Series D financing

Revance Therapeutics, Inc. (“Revance”) today announced the first $25 million closing of a $35 million Series D financing. The round was led by Essex Woodlands Health Ventures Fund VIII.

4 Jan 2010

Anesiva to file a petition for relief under the Bankruptcy Code

Anesiva, Inc. announced today that it was unable to satisfy the closing conditions set forth in the Agreement and Plan of Merger, dated August 4, 2009, among Anesiva, Arca Acquisition Corporation, a wholly-owned subsidiary of Anesiva, Arcion Therapeutics, Inc. ("Arcion") and, with respect to Articles V and IX only of the agreement, each of the Arcion stockholders listed on Schedule I thereto (the "Merger Agreement").

4 Jan 2010

Antigenics receives delisting notification letter from NASDAQ Stock Market

Antigenics Inc. announced that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the “Staff”) on December 30, 2009 indicating that the company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the “Bid Price Requirement”) because the bid price for the company’s common stock has closed below the minimum $1.00 per share requirement for 30 consecutive business days.

3 Jan 2010

Sharing Miracles: A TV program that features inspirational stories of real patients

Major League Baseball slugger Aaron Boone will be featured on January's episode of Sharing Miracles - a 30-minute public affairs television program that tells the compelling and inspirational stories of real patients. Sharing Miracles airs every week on more than 300 television stations nationwide.

31 Dec 2009

Origin Agritech completes Second Notes Repurchase Agreement with Citadel Equity Fund

Origin Agritech Limited (“Origin” or the “Company”) today announced that it completed its Second Notes Repurchase Agreement (the “Agreement”) as of December 30, 2009 with Citadel Equity Fund Ltd. (“Citadel”) of the remaining portion of the Company’s outstanding 1% Guaranteed Senior Secured Convertible Notes due 2012 (the “Notes”) by full repayment in cash of the agreed upon purchase price due to Citadel.

31 Dec 2009

Vitro Diagnostics completes private placement of common stock and warrants to raise cash infusion

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced the completion of a private placement of its common stock and warrants representing an initial investment of $87,500, with an additional $87,500 should the warrants be exercised, by a group of private investors who previously purchased the Company’s stock at a 36% lower price, through a prior private placement. Please see the associated Form 8-K for additional details regarding this transaction.

31 Dec 2009

Dentists, chiropractors and physical therapists to see rise in revenues from mid-2010: IBISWorld

With the economy showing signs of recovery, industry research firm IBISWorld analyzed more than 700 industries to identify the winning sectors in the coming year.

30 Dec 2009

Compugen raises $20M through sale of 4.1M ordinary shares

Compugen Ltd. today announced it has raised gross proceeds of $20 million, completing in full its previously announced Controlled Equity Offering facility. Under this facility, a total of approximately 4.1 million ordinary shares were sold at a weighted average price of approximately $4.91 per share. These shares were sold in the open market at prevailing prices during the period November 13, 2009 to December 29, 2009.

30 Dec 2009

U.S. PTO grants reissue patent concerning OSI Pharmaceuticals’ Tarceva

OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva’s® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a “Notice of Allowance” accepting the Company’s application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.

30 Dec 2009

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the David H. Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) today announced the publication of new data in the journal Proceedings of the National Academy of Sciences (PNAS) describing further advancements in discovery and development of novel “lipidoid” formulations for the systemic delivery of RNAi therapeutics.

30 Dec 2009

NeurAxon closes the sale of $8.75 million of unsecured subordinated convertible debentures

NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed the sale of approximately $8.75 million of unsecured subordinated 2.0% convertible debentures that are convertible under specified circumstances into existing class B preferred shares.

29 Dec 2009

Biotechnology News and Research

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

Dow AgroSciences to receive global license to develop and commercialize COT102 transgenic event

BioPlex 2200 Anti-CCP test for early detection of RA launched

Protein interaction linked to AMD

Vienna scientists develop new technique for producing H1N1 vaccines

Biological Industries named exclusive distributor of ATCC products in Israel

CBI signs definitive share purchase agreement to acquire GL Biochem

FDA grants Priority Review designation for InterMune's NDA for pirfenidone

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

Revance Therapeutics closes $35 million Series D financing

Anesiva to file a petition for relief under the Bankruptcy Code

Antigenics receives delisting notification letter from NASDAQ Stock Market

Sharing Miracles: A TV program that features inspirational stories of real patients

Origin Agritech completes Second Notes Repurchase Agreement with Citadel Equity Fund

Vitro Diagnostics completes private placement of common stock and warrants to raise cash infusion

Dentists, chiropractors and physical therapists to see rise in revenues from mid-2010: IBISWorld

Compugen raises $20M through sale of 4.1M ordinary shares

U.S. PTO grants reissue patent concerning OSI Pharmaceuticals’ Tarceva

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

NeurAxon closes the sale of $8.75 million of unsecured subordinated convertible debentures

Biotechnology eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News